Lynparza (Olaparib) for Breast Cancer

Overview
Lynparza is a prescription drug approved by the Food and Drug Administration (FDA) to treat metastatic breast cancer. Lynparza may be prescribed in either hormone receptor-positive or -negative cases, depending on previous treatments and other specific factors. Lynparza is also referred to by its drug name, Olaparib.

Lynparza is a targeted therapy in a class of drugs called poly ADP-ribose polymerase (PARP) inhibitors. Lynparza is believed to work by preventing cancer cells from repairing themselves once damaged by chemotherapy.

How do I take it?
Prescribing information states that Lynparza is taken twice daily.

Lynparza comes in tablet and capsule forms.

Side effects
The FDA-approved label for Lynparza lists common side effects including fatigue, weakness, headache, cold and flu symptoms, muscle and joint pain, mouth sores, strange taste in the mouth, decreased appetite, nausea, upset stomach, and constipation.

Rare but serious side effects listed for Lynparza include fetal harm, pneumonitis (lung inflammation), and myelodysplastic syndrome and acute myeloid leukemia, potentially fatal disorders of the bone marrow.

For more details about this treatment, visit:

Lynparza - AstraZeneca
https://www.lynparza.com/